Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.Frontiers in Oncology|August 23, 2021
Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin LymphomaRuimin Hong, Elaine Tan Su Yin, Linqin Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell TherapyMingming Zhang, Linghui Zhou, Houli Zhao, et al.Bone Marrow Transplantation|December 13, 2025
Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapyPingnan Xiao, Xin Zhao, Linqin Wang, et al.Nature Communications|September 9, 2022
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignanciesYongxian Hu, Jingjing Li, Fang Ni, et al.JAMA Oncology|April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical TrialMingming Zhang, Shan Fu, Jingjing Feng, et al.Cell Research|September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical studyYongxian Hu, Yali Zhou, Mingming Zhang, et al.The New England Journal of Medicine|April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisYongxian Hu, Mingming Zhang, Tingting Yang, et al.Journal of Hematology & Oncology|May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective studyHouli Zhao, Jieping Wei, Guoqing Wei, et al.American Journal of Hematology|May 14, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-UpHouli Zhao, Zhouning Lin, Haiqiong Zheng, et al.Pageof 4